{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T03:37:47Z","timestamp":1771472267634,"version":"3.50.1"},"reference-count":100,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:00:00Z","timestamp":1728950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bioengineering"],"abstract":"<jats:p>Targeted drug delivery has emerged as a transformative approach in the treatment of periorbital skin malignancies, offering the potential for enhanced efficacy and reduced side effects compared to traditional therapies. This review provides a comprehensive overview of targeted therapies in the context of periorbital malignancies, including basal cell carcinoma, squamous cell carcinoma, sebaceous gland carcinoma, and Merkel cell carcinoma. It explores the mechanisms of action for various targeted therapies, such as monoclonal antibodies, small molecule inhibitors, and immunotherapies, and their applications in treating these malignancies. Additionally, this review addresses the management of ocular and periocular side effects associated with these therapies, emphasizing the importance of a multidisciplinary approach to minimize impact and ensure patient adherence. By integrating current findings and discussing emerging trends, this review aims to highlight the advancements in targeted drug delivery and its potential to improve treatment outcomes and quality of life for patients with periorbital skin malignancies.<\/jats:p>","DOI":"10.3390\/bioengineering11101029","type":"journal-article","created":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T05:50:00Z","timestamp":1729230600000},"page":"1029","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeted Drug Delivery in Periorbital Non-Melanocytic Skin Malignancies"],"prefix":"10.3390","volume":"11","author":[{"given":"Benedetta","family":"Tirone","sequence":"first","affiliation":[{"name":"Dermatology and Venerology Section, Department of Precision and Regenerative Medicine and Ionan Area (DiMePRe-J), University of Bari Aldo Moro, 70124 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2993-8580","authenticated-orcid":false,"given":"Anna","family":"Scarabosio","sequence":"additional","affiliation":[{"name":"Clinic of Plastic and Reconstructive Surgery, Ospedale Santa Maria della Misericordia, 33100 Udine, Italy"},{"name":"Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7721-4694","authenticated-orcid":false,"given":"Pier Luigi","family":"Surico","sequence":"additional","affiliation":[{"name":"Schepens Eye Research Institute of Mass Eye and Ear, Harvard Medical School, Boston, MA 02114, USA"},{"name":"Department of Ophthalmology, Campus Bio-Medico University, 00128 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier Camillo","family":"Parodi","sequence":"additional","affiliation":[{"name":"Clinic of Plastic and Reconstructive Surgery, Ospedale Santa Maria della Misericordia, 33100 Udine, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7938-876X","authenticated-orcid":false,"given":"Fabiana","family":"D\u2019Esposito","sequence":"additional","affiliation":[{"name":"Imperial College Ophthalmic Research Group (ICORG) Unit, Imperial College, 153-173 Marylebone Rd, London NW15QH, UK"},{"name":"Department of Neurosciences, Reproductive Sciences and Dentistry, University of Naples Federico II, Via Pansini 5, 80131 Napoli, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1051-876X","authenticated-orcid":false,"given":"Alessandro","family":"Avitabile","sequence":"additional","affiliation":[{"name":"Eye Clinic Catania San Marco Hospital, Viale Carlo Azeglio Ciampi, 95121 Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Foti","sequence":"additional","affiliation":[{"name":"Dermatology and Venerology Section, Department of Precision and Regenerative Medicine and Ionan Area (DiMePRe-J), University of Bari Aldo Moro, 70124 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8424-0068","authenticated-orcid":false,"given":"Caterina","family":"Gagliano","sequence":"additional","affiliation":[{"name":"Mediterranean Foundation \u201cG.B. Morgagni\u201d, 95125 Catania, Italy"},{"name":"Department of Medicine and Surgery, University of Enna \u201cKore\u201d, 94100 Enna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0999-5545","authenticated-orcid":false,"given":"Marco","family":"Zeppieri","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Hospital of Udine, p.le S. Maria della Misericordia 15, 33100 Udine, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ejphar.2018.07.034","article-title":"Molecular targeted therapy: Treating cancer with specificity","volume":"834","author":"Lee","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41568-022-00529-3","article-title":"The coming decade in precision oncology: Six riddles","volume":"23","author":"Wahida","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"100646","DOI":"10.1016\/j.drup.2019.100646","article-title":"The emergence of drug resistance to targeted cancer therapies: Clinical evidence","volume":"47","author":"Scorilas","year":"2019","journal-title":"Drug Resist. Updates"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.2174\/1567201818666210609161301","article-title":"Targeted Drug Delivery: Trends and Perspectives","volume":"18","author":"Ashique","year":"2021","journal-title":"Curr. Drug Deliv."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"150927","DOI":"10.1016\/j.soncn.2019.08.006","article-title":"An Overview of Monoclonal Antibodies","volume":"35","author":"Bayer","year":"2019","journal-title":"Semin. Oncol. Nurs."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.1158\/0008-5472.CAN-21-1109","article-title":"Mechanisms of Therapeutic Antitumor Monoclonal Antibodies","volume":"81","author":"Tsao","year":"2021","journal-title":"Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S1470-2045(16)30030-4","article-title":"Antibody\u2013drug conjugates for cancer therapy","volume":"17","author":"Thomas","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.blre.2018.02.004","article-title":"Bispecific antibody based therapeutics: Strengths and challenges","volume":"32","author":"Thakur","year":"2018","journal-title":"Blood Rev."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Delgado, M., and Garcia-Sanz, J.A. (2023). Therapeutic Monoclonal Antibodies against Cancer: Present and Future. Cells, 12.","DOI":"10.3390\/cells12242837"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ctrv.2016.02.009","article-title":"New perspectives on complement mediated immunotherapy","volume":"45","author":"Blom","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1080\/19420862.2018.1466767","article-title":"The \u201cless-is-more\u201d in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity","volume":"10","author":"Pereira","year":"2018","journal-title":"mAbs"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"552","DOI":"10.2174\/1389201022666210820093608","article-title":"Antibody-Dependent Cell-Mediated Cytotoxicity Through Natural Killer (NK) Cells: Unlocking NK Cells for Future Immunotherapy","volume":"23","author":"Chin","year":"2021","journal-title":"Curr. Pharm. Biotechnol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"eabl9171","DOI":"10.1126\/sciadv.abl9171","article-title":"Promoting antibody-dependent cellular phagocytosis for effective macrophage-based cancer immunotherapy","volume":"8","author":"Cao","year":"2022","journal-title":"Sci. Adv."},{"key":"ref_14","first-page":"1055","article-title":"Co-Stimulatory Agonists: An Insight into the Immunotherapy of Cancer","volume":"20","author":"Pourakbari","year":"2021","journal-title":"EXCLI J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.ccell.2022.10.015","article-title":"CD16+ fibroblasts foster a trastuzumab-refractory microenvironment that is reversed by VAV2 inhibition","volume":"40","author":"Liu","year":"2022","journal-title":"Cancer Cell"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: Advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"432","DOI":"10.12998\/wjcc.v2.i9.432","article-title":"Targeting EGFR and sonic hedgehog pathways for locally advanced eyelid and periocular carcinomas","volume":"2","author":"Yin","year":"2014","journal-title":"World J. Clin. Cases"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3109\/08820538.2013.825278","article-title":"The Role of Genetics in the Pathogenesis of Periocular Cutaneous Neoplasms: Implications for Targeted Therapy","volume":"28","author":"Lee","year":"2013","journal-title":"Semin. Ophthalmol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.prp.2011.03.002","article-title":"Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: Molecular bases for EGFR-targeted therapy","volume":"207","author":"Uribe","year":"2011","journal-title":"Pathol. Res. Pract."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1200\/JCO.2010.34.1735","article-title":"Phase II Study of Cetuximab as First-Line Single-Drug Therapy in Patients with Unresectable Squamous Cell Carcinoma of the Skin","volume":"29","author":"Maubec","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1001\/archophthalmol.2012.2515","article-title":"Epidermal Growth Factor Receptor Inhibitors for Treatment of Orbital Squamous Cell Carcinoma","volume":"130","author":"Sabichi","year":"2012","journal-title":"Arch. Ophthalmol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/annonc\/mdr367","article-title":"Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and\/or metastatic squamous cell carcinoma of head and neck","volume":"23","author":"Hitt","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"de Mello, R.A., Ger\u00f3s, S., Alves, M.P., Moreira, F., Avezedo, I., and Dinis, J. (2014). Cetuximab Plus Platinum-Based Chemotherapy in Head and Neck Squamous Cell Carcinoma: A Retrospective Study in a Single Comprehensive European Cancer Institution. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0086697"},{"key":"ref_24","first-page":"1681","article-title":"Results of radiotherapy plus Cetuximab for squamous cell carcinoma of the head and neck","volume":"60","author":"Tsuchida","year":"2015","journal-title":"Jpn. J. Clin. Radiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1093\/annonc\/mdy040","article-title":"Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02)","volume":"29","author":"Tahara","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3889\/oamjms.2018.022","article-title":"Chimeric Monoclonal Antibody Cetuximab Targeting Epidermal Growth Factor-Receptor in Advanced Non-Melanoma Skin Cancer","volume":"6","author":"Wollina","year":"2018","journal-title":"Open Access Maced. J. Med. Sci."},{"key":"ref_27","unstructured":"Howell, J.Y., and Ramsey, M.L. (2024, September 01). Squamous Cell Skin Cancer, StatPearls [lntermet], Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/28722968\/."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Jiang, R., Fritz, M., and Que, S.K.T. (2024). Cutaneous Squamous Cell Carcinoma: An Updated Review. Cancers, 16.","DOI":"10.3390\/cancers16101800"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.aopr.2024.02.003","article-title":"Personalized treatment concepts in extraocular cancer","volume":"4","author":"Ju","year":"2024","journal-title":"Adv. Ophthalmol. Pract. Res."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Trotier, D.C., Huang, L., van Landingham, S.W., Burr, A.R., and Ma, V.T. (2024). Review of recent advances in managing periocular skin malignancies. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1275930"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Patel, B., and Saba, N.F. (2021). Current Aspects and Future Considerations of EGFR Inhibition in Locally Advanced and Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck. Cancers, 13.","DOI":"10.3390\/cancers13143545"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/ICU.0000000000000403","article-title":"Molecularly targeted agents in oculoplastic surgery","volume":"28","author":"Allen","year":"2017","journal-title":"Curr. Opin. Ophthalmol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1093\/annonc\/mdu368","article-title":"Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma","volume":"25","author":"Foote","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1007\/s11033-018-4427-x","article-title":"Monoclonal antibodies in cancer immunotherapy","volume":"45","year":"2018","journal-title":"Mol. Biol. Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: Understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"111876","DOI":"10.1016\/j.ejmech.2019.111876","article-title":"Progress in PD-1\/PD-L1 pathway inhibitors: From biomacromolecules to small molecules","volume":"186","author":"Lin","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Alsaab, H.O., Sau, S., Alzhrani, R., Tatiparti, K., Bhise, K., Kashaw, S.K., and Iyer, A.K. (2017). PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome. Front. Pharmacol., 8.","DOI":"10.3389\/fphar.2017.00561"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/978-981-15-3266-5_3","article-title":"Roles of PD-1\/PD-L1 Pathway: Signaling, Cancer, and Beyond","volume":"1248","author":"Ai","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1126\/science.aaf1292","article-title":"T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition","volume":"355","author":"Hui","year":"2017","journal-title":"Science"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1126\/science.aaf0683","article-title":"Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent","volume":"355","author":"Kamphorst","year":"2017","journal-title":"Science"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination","volume":"13","author":"Boutros","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Tang, Q., Chen, Y., Li, X., Long, S., Shi, Y., Yu, Y., Wu, W., Han, L., and Wang, S. (2022). The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.964442"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/jdv.15845","article-title":"Advanced cutaneous squamous cell carcinoma: Real world data of patient profiles and treatment patterns","volume":"33","author":"Amaral","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.annonc.2021.07.008","article-title":"Pembrolizumab for locally advanced and recurrent\/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): An open-label, nonrandomized, multicenter, phase II trial","volume":"32","author":"Hughes","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJMoa2209813","article-title":"Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma","volume":"387","author":"Gross","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1136\/bjophthalmol-2021-319417","article-title":"Immune checkpoint inhibitors for treatment of periorbital squamous cell carcinoma","volume":"107","author":"Goldfarb","year":"2023","journal-title":"Br. J. Ophthalmol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/IOP.0000000000002190","article-title":"Cemiplimab for Orbital Squamous Cell Carcinoma in 11 Cases","volume":"38","author":"Steren","year":"2022","journal-title":"Ophthalmic Plast. Reconstr. Surg."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1038\/s41433-022-02358-y","article-title":"Primary cemiplimab treatment for orbital squamous cell carcinoma is effective and may alleviate the need for orbital exenteration","volume":"37","author":"Tiosano","year":"2023","journal-title":"Eye"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"17077","DOI":"10.1038\/nrdp.2017.77","article-title":"Merkel cell carcinoma","volume":"3","author":"Becker","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_52","first-page":"e15292","article-title":"Merkel cell carcinoma: An updated review of pathogenesis, diagnosis, and treatment options","volume":"35","author":"Hernandez","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jaad.2024.04.039","article-title":"Merkel cell carcinoma","volume":"91","author":"Thakker","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e002646","DOI":"10.1136\/jitc-2021-002646","article-title":"First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): Primary and biomarker analyses of a phase II study","volume":"9","author":"Mortier","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e000674","DOI":"10.1136\/jitc-2020-000674","article-title":"Avelumab in patients with previously treated metastatic Merkel cell carcinoma: Long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial","volume":"8","author":"Bhatia","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"100290","DOI":"10.1016\/j.esmoop.2021.100290","article-title":"Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): Updated overall survival data after >5 years of follow-up","volume":"6","author":"Bhatia","year":"2021","journal-title":"ESMO Open"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e002478","DOI":"10.1136\/jitc-2021-002478","article-title":"Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma","volume":"9","author":"Nghiem","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_58","first-page":"574","article-title":"Abstracts 545","volume":"9","author":"Vinohrady","year":"2021","journal-title":"MCC"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"9506","DOI":"10.1200\/JCO.2023.41.16_suppl.9506","article-title":"Non-comparative, open-label, international, multicenter phase I\/II study of nivolumab (NIVO) \u00b1 ipilimumab (IPI) in patients (pts) with recurrent\/metastatic merkel cell carcinoma (MCC) (CheckMate 358)","volume":"41","author":"Bhatia","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1200\/JCO.20.00201","article-title":"Neoadjuvant Nivolumab for Patients with Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial","volume":"38","author":"Topalian","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"12065","DOI":"10.1002\/cam4.5890","article-title":"Avelumab for the treatment of locally advanced or metastatic Merkel cell carcinoma\u2014A multicenter real-world experience in Israel","volume":"12","author":"Averbuch","year":"2023","journal-title":"Cancer Med."},{"key":"ref_62","unstructured":"Network NCC (2019). NCCN Clinical Practice Guidelines in Oncology: Basal Cell Skin Cancer, NCCN Evid Blocks."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.2217\/imt-2021-0089","article-title":"Immune Checkpoint Inhibitors for Advanced or Metastatic Basal Cell Carcinoma: How much Evidence do we Need?","volume":"13","author":"Moujaess","year":"2021","journal-title":"Immunotherapy"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"106552","DOI":"10.1016\/j.phrs.2022.106552","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update","volume":"187","author":"Roskoski","year":"2023","journal-title":"Pharmacol. Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev-pharmtox-010919-023603","article-title":"Proteasome Inhibitor Drugs","volume":"60","author":"Fricker","year":"2020","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/82_2018_137","article-title":"Small\u2014Molecule Inhibitors of PARPs: From Tools for Investigating ADP\u2014Ribosylation to Therapeutics","volume":"420","author":"Profiling","year":"2018","journal-title":"Act. Based Protein Profiling"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1590\/abd1806-4841.20176544","article-title":"Molecular basis of basal cell carcinoma","volume":"92","author":"Montagna","year":"2017","journal-title":"An. Bras. Dermatol."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Sekulic, A., Migden, M.R., Basset-Seguin, N., Garbe, C., Gesierich, A., Lao, C.D., Miller, C., Mortier, L., Murrell, D.F., and Hamid, O. (2017). Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: Final update of the pivotal ERIVANCE BCC study. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3286-5"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ejca.2017.08.022","article-title":"Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial","volume":"86","author":"Hauschild","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"100844","DOI":"10.1016\/j.eclinm.2021.100844","article-title":"Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study): Neoadjuvant Vismodegib in Locally Advanced Basal Cell Carcinoma","volume":"35","author":"Bertrand","year":"2021","journal-title":"eClinicalMedicine"},{"key":"ref_71","first-page":"e1240","article-title":"Vismodegib for Preservation of Visual Function in Patients with Advanced Periocular Basal Cell Carcinoma: The VISORB Trial","volume":"26","author":"Kahana","year":"2021","journal-title":"Oncololgy"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/IOP.0000000000000388","article-title":"Efficacy of Vismodegib (Erivedge) for Basal Cell Carcinoma Involving the Orbit and Periocular Area","volume":"31","author":"Demirci","year":"2015","journal-title":"Ophthalmic Plast. Reconstr. Surg."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/jamaophthalmol.2013.5018","article-title":"Vismodegib for Periocular and Orbital Basal Cell Carcinoma","volume":"131","author":"Gill","year":"2013","journal-title":"JAMA Ophthalmol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ajo.2015.04.040","article-title":"Hedgehog Pathway Inhibition for Locally Advanced Periocular Basal Cell Carcinoma and Basal Cell Nevus Syndrome","volume":"160","author":"Ozgur","year":"2015","journal-title":"Am. J. Ophthalmol."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Unsworth, S.P., Tingle, C.F., Heisel, C.J., Eton, E.A., Andrews, C.A., Chan, M.P., Bresler, S.C., and Kahana, A. (2022). Analysis of residual disease in periocular basal cell carcinoma following hedgehog pathway inhibition: Follow up to the VISORB trial. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0265212"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41433-021-01493-2","article-title":"Vismodegib improves quality of life in patients with periocular locally advanced basal cell carcinoma: Subgroup analysis, STEVIE trial","volume":"36","author":"Gershoni","year":"2022","journal-title":"Eye"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/bjd.18552","article-title":"Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study","volume":"182","author":"Dummer","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1158\/1078-0432.CCR-11-1951","article-title":"A Phase II Study of Gefitinib for Aggressive Cutaneous Squamous Cell Carcinoma of the Head and Neck","volume":"18","author":"Lewis","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jaad.2009.12.042","article-title":"Metastatic cutaneous squamous cell carcinoma responding to erlotinib therapy","volume":"65","author":"Engelhardt","year":"2011","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1038\/s41467-020-19505-2","article-title":"The once and future gene therapy","volume":"11","author":"Bulaklak","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e3550","DOI":"10.1002\/jgm.3550","article-title":"Gene therapy in cancer","volume":"25","year":"2023","journal-title":"J. Gene Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.omtn.2018.11.007","article-title":"Antisense Oligonucleotides Targeting Angiogenic Factors as Potential Cancer Therapeutics","volume":"14","author":"LE","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"E61","DOI":"10.1208\/aapsj070109","article-title":"DNA-based therapeutics and DNA delivery systems: A comprehensive review","volume":"7","author":"Patil","year":"2005","journal-title":"AAPS J."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/2643-3230.BCD-21-0084","article-title":"Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy","volume":"2","author":"Elsallab","year":"2021","journal-title":"Blood Cancer Discov."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Ma, C.-C., Wang, Z.-L., Xu, T., He, Z.-Y., and Wei, Y.-Q. (2020). The approved gene therapy drugs worldwide: From 1998 to 2019. Biotechnol. Adv., 40.","DOI":"10.1016\/j.biotechadv.2019.107502"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Jommi, C., Bramanti, S., Pani, M., Ghirardini, A., and Santoro, A. (2022). CAR T-Cell Therapies in Italy: Patient Access Barriers and Recommendations for Health System Solutions. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.915342"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"117018","DOI":"10.1016\/j.lfs.2019.117018","article-title":"A gene-based anti-angiogenesis therapy as a novel strategy for cancer treatment","volume":"239","author":"Fallah","year":"2019","journal-title":"Life Sci."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.addr.2011.06.010","article-title":"Mesenchymal stem cells engineered for cancer therapy","volume":"64","author":"Shah","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41392-023-01642-x","article-title":"Smart nanoparticles for cancer therapy","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"12320","DOI":"10.1002\/anie.201403036","article-title":"Engineered Nanoparticles for Drug Delivery in Cancer Therapy","volume":"53","author":"Sun","year":"2014","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Amreddy, N., Babu, A., Muralidharan, R., Panneerselvam, J., Srivastava, A., Ahmed, R., Mehta, M., Munshi, A., and Ramesh, R. (2017). Recent Advances in Nanoparticle-Based Cancer Drug and Gene Delivery, Elsevier Inc.. [1st ed.].","DOI":"10.1016\/bs.acr.2017.11.003"},{"key":"ref_92","first-page":"20180032","article-title":"Passive and active targeting in cancer therapy by liposomes and lipid nanoparticles","volume":"34","author":"Alavi","year":"2019","journal-title":"Drug Metab. Pers. Ther."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Li, J., Wang, Q., Xia, G., Adilijiang, N., Li, Y., Hou, Z., Fan, Z., and Li, J. (2023). Recent Advances in Targeted Drug Delivery Strategy for Enhancing Oncotherapy. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15092233"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"7921","DOI":"10.7150\/thno.49577","article-title":"The EPR effect and beyond: Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy","volume":"10","author":"Shi","year":"2020","journal-title":"Theranostics"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1002\/cplu.202000496","article-title":"Development of High-Drug-Loading Nanoparticles","volume":"85","author":"Liu","year":"2020","journal-title":"Chempluschem"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"114198","DOI":"10.1016\/j.addr.2022.114198","article-title":"Nanoparticle enhanced blue light therapy","volume":"184","author":"Akasov","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.biomaterials.2017.05.013","article-title":"Surface design of magnetic nanoparticles for stimuli-responsive cancer imaging and therapy","volume":"136","author":"Kang","year":"2017","journal-title":"Biomaterials"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Yoon, H.-M., Kang, M.-S., Choi, G.-E., Kim, Y.-J., Bae, C.-H., Yu, Y.-B., and Jeong, Y.-I. (2021). Stimuli-Responsive Drug Delivery of Doxorubicin Using Magnetic Nanoparticle Conjugated Poly(ethylene glycol)-g-Chitosan Copolymer. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222313169"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"6827","DOI":"10.2147\/IJN.S269321","article-title":"Pathological Mechanism of Photodynamic Therapy and Photothermal Therapy Based on Nanoparticles","volume":"15","author":"Hou","year":"2020","journal-title":"Int. J. Nanomed."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/cgt.2017.16","article-title":"New methods in the diagnosis of cancer and gene therapy of cancer based on nanoparticles","volume":"24","author":"Zaimy","year":"2017","journal-title":"Cancer Gene Ther."}],"container-title":["Bioengineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2306-5354\/11\/10\/1029\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:13:50Z","timestamp":1760112830000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2306-5354\/11\/10\/1029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,15]]},"references-count":100,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["bioengineering11101029"],"URL":"https:\/\/doi.org\/10.3390\/bioengineering11101029","relation":{},"ISSN":["2306-5354"],"issn-type":[{"value":"2306-5354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,15]]}}}